EBIT: Income before interest and taxes.
Atossa Therapeutics, Inc. (ATOS) had EBIT of $-5.90M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-5.64M |
|
-- |
|
-- |
|
$5.90M |
|
$-5.90M |
|
$0.26M |
|
$-5.64M |
|
$-5.64M |
|
$-5.64M |
|
$-5.64M |
|
$-5.64M |
|
$-5.64M |
|
|
EBIT |
$-5.90M |
$-5.89M |
|
9.99M |
|
9.99M |
|
$-0.56 |
|
$-0.56 |
|
| Balance Sheet Financials | |
$25.18M |
|
-- |
|
$1.27M |
|
$26.45M |
|
$4.71M |
|
-- |
|
-- |
|
$4.71M |
|
$21.74M |
|
$21.74M |
|
$21.74M |
|
9.98M |
|
| Cash Flow Statement Financials | |
$-24.75M |
|
-- |
|
$4.02M |
|
$41.41M |
|
$20.68M |
|
$-20.73M |
|
$2.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.75M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-25.93% |
|
-25.93% |
|
-21.32% |
|
-25.93% |
|
$2.18 |
|
$-2.48 |
|
$-2.48 |
|